EE17 Economic Evaluation of Patiromer for the Treatment of Hyperkalaemia in CKD Patients With and Without HF in Italy

Abstract

Chronic kidney disease (CKD) patients with and without Heart failure (HF) are at risk of developing hyperkalaemia (HK), which is further heightened with the necessary use of renin–angiotensin–aldosterone system inhibitor (RAASi) therapy. Current standard of care (SoC) for HK is limited and often necessitates RAASi down-titration/discontinuation, resulting in detrimental outcomes. This study assessed the cost-effectiveness of patiromer for HK treatment in CKD patients with and without HF in an Italian setting.